Skip to main content
NCBI home page
Journal of Medical Toxicology logoLink to Journal of Medical Toxicology
. 2010 May 15;6(2):85–93. doi: 10.1007/s13181-010-0073-y

Comparative Hemodynamic Effects of Levosimendan Alone and in Conjunction with 4-Aminopyridine or Calcium Chloride in a Rodent Model of Severe Verapamil Poisoning

Andis Graudins 1,2,✉, Kathy Ka Ling Wong 2
PMCID: PMC3550276  PMID: 20473651

Abstract

Levosimendan (Levo) increases sensitivity of troponin-C to calcium, thus increasing myocardial contractility. It is also a vascular K+-ATP channel agonist producing peripheral vasodilation. Previous research with levosimendan revealed an increase in cardiac output (CO) but not blood pressure (BP) in experimental verapamil poisoning. Levosimendan’s K+-channel agonist properties may augment verapamil’s vasodilatory effects. 4-Aminopyridine (4-AP) is a K+-channel antagonist. It has successfully reversed hypotension in experimental verapamil poisoning. We hypothesized that coadministration of these agents may improve BP and CO in verapamil poisoning. Anesthetized, ventilated, and canulated male Wistar rats were poisoned with verapamil. Animals received one of six treatments, which are as follows: (1) n-saline infusion (control), (2) Levo 6.25 μg/kg loading dose and 36 μg/kg/h infusion, (3) 4-AP 2 mg/kg loading dose and infusion (4-AP), (4) Levo+4-AP, (5) CaCl2 loading dose and infusion, and (6) Levo+CaCl2. Hemodynamic parameters were recorded for 60 min. Outcome measures were changes in CO, BP, and heart rate (HR) compared to control. All groups had similar pretoxicity and peak toxicity CO (50% of pretoxicity value), BP (50% or pretoxicity value), and HR. Control group CO, BP, and HR progressively dropped during the verapamil infusion. Levosimendan produced a statistically significant improvement in CO (75% of pretoxicity level) but not BP in comparison to control. 4-AP produced a significant improvement in CO (110% of pretoxicity) and BP (78% of pretoxicity). Levo+4-AP and Levo+CaCl2 groups improved CO (100% of pretoxicity) and BP (77% and 50% of pretoxicity, respectively), but there was no additive increase in CO or BP in animals compared to 4-AP or CaCl2 alone. Levosimendan moderately improved CO but not BP in verapamil poisoning. The hypotensive effects of levosimendan were not overcome by coadministration of either 4-AP or CaCl2. Levosimendan may not be an appropriate agent to use in the treatment of verapamil poisoning.

Keywords: Poisoning, Overdose, Calcium channel blockers, Verapamil, Levosimendan, Aminopyridine, Rodent

Full Text

The Full Text of this article is available as a PDF (224.8 KB).

Acknowledgments

Disclosures

Research is funded by a 2007 American College of Medical Toxicology/Orphan Medical Antidote Research Grant.

Footnotes

Levosimendan donated for research purposes by Abbott Australasia, Pty Ltd.

References

  • 1.Huang L, Weil MH, Sun S, Cammarata G, Cao L, Tang W. Levosimendan improves postresuscitation outcomes in a rat model of CPR. J Lab Clin Med. 2005;146(5):256–261. doi: 10.1016/j.lab.2005.07.005. [DOI] [PubMed] [Google Scholar]
  • 2.Huang L, Weil MH, Tang W, Sun S, Wang J. Comparison between dobutamine and levosimendan for management of postresuscitation myocardial dysfunction. Crit Care Med. 2005;33(3):487–491. doi: 10.1097/01.CCM.0000156241.55872.15. [DOI] [PubMed] [Google Scholar]
  • 3.Lehtonen L. Levosimendan: a calcium-sensitizing agent for the treatment of patients with decompensated heart failure. Curr Heart Fail Rep. 2004;1(3):136–144. doi: 10.1007/s11897-004-0023-6. [DOI] [PubMed] [Google Scholar]
  • 4.Graudins A, Najafi JM, Perry M. Treatment of experimental verapamil poisoning with levosimendan utilizing a rodent model of drug toxicity. Clin Toxicol. 2008;46(1):50–56. doi: 10.1080/15563650701665092. [DOI] [PubMed] [Google Scholar]
  • 5.Najafi JM, Graudins A. Norepinephrine co-administered with levosimendan does not reverse hypotension in a rodent model experimental verapamil poisoning (abstract) Emerg Med Australas. 2007;19(Suppl 1):A19–A20. [Google Scholar]
  • 6.Magdalan J. New treatment methods in verapamil poisoning: experimental studies. Pol J Pharmacol. 2003;55(3):425–432. [PubMed] [Google Scholar]
  • 7.Magdalan J, Kochman K, Antonczyk A, Przewlocki M, Smolarek M. Successful treatment by 4-aminopyridine of three cases of severe verapamil poisoning. Przegl Lek. 2003;60(4):271–273. [PubMed] [Google Scholar]
  • 8.Hill MA, Larkins RG. Alterations in distribution of cardiac output in experimental diabetes in rats. Am J Physiol. 1989;257(2 Part 2):H571–H580. doi: 10.1152/ajpheart.1989.257.2.H571. [DOI] [PubMed] [Google Scholar]
  • 9.Follath F. Levosimendan in patients with low-output heart failure: lessons from the LIDO trial. Ital Heart J. 2003;4(Suppl 2):34S–38S. [PubMed] [Google Scholar]
  • 10.Nijhawan N, Nicolosi AC, Montgomery MW, Aggarwal A, Pagel PS, Warltier DC. Levosimendan enhances cardiac performance after cardiopulmonary bypass: a prospective, randomized placebo-controlled trial. J Cardiovasc Pharmacol. 1999;34(2):219–228. doi: 10.1097/00005344-199908000-00007. [DOI] [PubMed] [Google Scholar]
  • 11.Lehtonen LA. Levosimendan: a parenteral calcium-sensitising drug with additional vasodilatory properties. Expert Opin Investig Drugs. 2001;10(5):955–970. doi: 10.1517/13543784.10.5.955. [DOI] [PubMed] [Google Scholar]
  • 12.Tuncok Y, Apaydin S, Gelal A, Ates M, Guven H. The effects of 4-aminopyridine and Bay K 8644 on verapamil-induced cardiovascular toxicity in rats. J Toxicol - Clin Toxicol. 1998;36(4):301–307. doi: 10.3109/15563659809028025. [DOI] [PubMed] [Google Scholar]
  • 13.Agoston S, Maestrone E, van Hezik EJ, Ket JM, Houwertjes MC, Uges DR. Effective treatment of verapamil intoxication with 4-aminopyridine in the cat. J Clin Invest. 1984;73(5):1291–1296. doi: 10.1172/JCI111331. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Gay R, Algeo S, Lee RJ, Olajo M, Morkin E, Goldman S. Treatment of verapamil toxicity in intact dogs. J Clin Invest. 1986;77(6):1805–1811. doi: 10.1172/JCI112505. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Stork CM, Hoffman RS. Characterization of 4-aminopyridine in overdose. J Toxicol - Clin Toxicol. 1994;32(5):583–587. doi: 10.3109/15563659409011063. [DOI] [PubMed] [Google Scholar]
  • 16.Buckley N, Dawson AH, Howarth D, Whyte IM. Slow-release verapamil poisoning. Use of polyethylene glycol whole-bowel lavage and high-dose calcium. Med J Aust. 1993;158(3):202–204. [PubMed] [Google Scholar]
  • 17.Slawsky MT, Colucci WS, Gottlieb SS, Greenberg BH, Haeusslein E, Hare J, et al. Acute hemodynamic and clinical effects of levosimendan in patients with severe heart failure. Study Investigators. Circulation. 2000;102(18):2222–2227. doi: 10.1161/01.cir.102.18.2222. [DOI] [PubMed] [Google Scholar]
  • 18.Buelke-Sam J, Holson JF, Bazare JJ, Young JF. Comparative stability of physiological parameters during sustained anesthesia in rats. Lab Anim Sci. 1978;28(2):157–162. [PubMed] [Google Scholar]

Articles from Journal of Medical Toxicology are provided here courtesy of Springer

RESOURCES